Improved survival in MDS patients receiving iron chelation therapy - A matched pair analysis of 188 patients from the Dusseldorf MDS registry

MDS patients are prone to develop transfusional iron overload. Iron overload may partly explain why transfusion dependency is associated with a decreased likelihood of survival. Our matched-pair analysis included 94 patients on long-term chelation therapy and 94 matched patients without it. All patients had iron overload, defined as serum ferritin (SF) above 1000 ng/ml or a history of multiple transfusions and SF >= 500 ng/ml. Median SF was 1954 ng/ml in chelated and 875 ng/ml in non-chelated patients. The difference in median survival (74 vs. 49 months, respectively; p = 0.002) supports the idea that iron chelation therapy is beneficial for MDS patients. (C) 2012 Elsevier Ltd. All rights reserved.